Influence of drug containing ginger extract on arthritic pain and gastropathy in patients with osteoarthritis

ISRCTN ISRCTN48110500
DOI https://doi.org/10.1186/ISRCTN48110500
Secondary identifying numbers 616-08:612.018;612.4:616.7
Submission date
07/08/2010
Registration date
26/11/2010
Last edited
26/11/2010
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Vladimir Drozdov
Scientific

Central Scientific Research Institute of Gastroenterology
Shosse Entuziastov,86
Moscow
111123
Russian Federation

Phone +7 (8)495 304 1942
Email zvopt@yandex.ru

Study information

Study designRandomised active controlled clinical trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Other
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet (Russian only)
Scientific titleInfluence of drug containing ginger extract on arthritic pain and gastropathy in patients with osteoarthritis: a randomised active controlled clinical trial
Study objectivesTraditional non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX-1,2 expression leading to the lack of prostaglandins (PG). PG play a crucial role in mechanisms of mucosal defense. This drug containing ginger extract inhibits COX-2 and increases PG production in gastric mucosa. It seems to be an alternative to traditional NSAIDs especially in patients with osteoarthritis with risk factors of NSAID-induced gastropathy.
Ethics approval(s)Local Ethics Committee of Central Scientific Research Institute of Gastroenterology approved on the 31st August 2007
Health condition(s) or problem(s) studiedOsteoarthritis, NSAID-induced gastropathy
InterventionThe patients were randomised in two groups, using methods of envelopes, to:
1. Group ZG (n = 21): ginger and glucosamine combination (Zinaxin Glucosamine: 170 mg ginger extract [Zingiber officinalis, EV.EXT 35] and 500 mg glucosamine, as glucosamine sulphate, per capsule, Ferrosan AS, Denmark) 2 capsules orally daily
2. Group DG (n = 22): diclofenac and glucosamine combination (100 mg diclofenac as sodium diclofenac and 1000 mg glucosamine as glucosamine sulphate) daily

The duration of treatment was 28 days.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase IV
Drug / device / biological / vaccine name(s)Ginger extract, diclofenac
Primary outcome measureUpper GI lesions (erosion, ulcer) were assessed on the 28 day of treatment with upper GI endoscopy
Secondary outcome measuresGastritis
Overall study start date01/06/2008
Completion date01/06/2009

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants40
Key inclusion criteria1. Aged over 18 years, either sex
2. Osteoarthritis (OA) pain syndrome availability of more than 40 mm according to Visual Analogue Scale (VAS)
3. Requiring anti-inflammatory therapy assignment
4. NSAID-gastropathy or dyspepsia development from NSAID therapy in anamnesis
5. Informed patient consent to administer the preparation
6. Compliance with the listed research protocol
Key exclusion criteria1. Ulcer presence during upper gastrointestinal (GI) endoscopy and more than 5 stomach mucosa and/or duodenum erosions, and/or erosive oesophagitis
2. High risk of cardiological complications, arterial hypertension, cardiac insufficiency greater than II degree, myocardial infarction or apoplectic attack in anamnesis during the previous 3 years, chronic kidney disease, liver insufficiency, bronchial asthma, subcompensated or decompensated diabetes mellitus, oncological diseases
3. NSAID administration, aspirin in anti-aggregant doses, glucocorticosteroids
4. Pregnancy
Date of first enrolment01/06/2008
Date of final enrolment01/06/2009

Locations

Countries of recruitment

  • Russian Federation

Study participating centre

Central Scientific Research Institute of Gastroenterology
Moscow
111123
Russian Federation

Sponsor information

Central Scientific Research Institute of Gastroenterology (Russia)
Research organisation

c/o Vladimir N. Drozdov
Shosse Entuziastov, 86
Moscow
111123
Russian Federation

Phone +7 (8)495 304 1942
Email zvopt@yandex.ru

Funders

Funder type

Research organisation

Central Scientific Research Institute of Gastroenterology (Russia) - Healthcare Department

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan